Premium
Prospective medical assessment of adults surviving childhood cancer: Study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study
Author(s) -
Hudson Melissa M.,
Ness Kirsten K.,
Nolan Vikki G.,
Armstrong Gregory T.,
Green Daniel M.,
Morris E. Bran,
Spunt Sheri L.,
Metzger Monika L.,
Krull Kevin R.,
Klosky James L.,
Srivastava Deo Kumar,
Robison Leslie L.
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22875
Subject(s) - medicine , cohort , prospective cohort study , cohort study , pediatric cancer , cancer , childhood cancer , pediatrics , family medicine
Background To facilitate prospective medical assessment of adults surviving pediatric malignancies and advance knowledge about long‐term childhood cancer survivor health, St. Jude Children's Research Hospital (SJCRH) is establishing a lifetime cohort of survivors. Methods Eligibility criteria for inclusion in the St. Jude Lifetime Cohort (SJLIFE) study include: (1) diagnosis of childhood malignancy treated at SJCRH; (2) survival ≥ 10 years from diagnosis; and (3) current age ≥18 years. Three levels of participation are offered: (1) comprehensive evaluation on SJCRH campus; (2) limited home evaluation; or (3) completion of health surveys only. A systematic recruitment structure based upon blocks of 50 patients initially focused on leukemia and lymphoma survivors and patients eligible for pilot studies. Results As of January 1, 2010, 1,625 (42%) of 3,900 eligible ≥10‐year survivors have been contacted. Among the first 1,000 potentially eligible survivors selected for recruitment, 971 were subsequently confirmed to fulfill eligibility criteria. To date, 898/971 (92.5%) have been successfully contacted of whom 825 (91.8%) have agreed to participate. Among participants, 88.6% agreed to comprehensive medical evaluation, 0.4% limited local evaluation, and 11.0% survey only. Anticipated minimum overall participation rate for medical evaluation is 75.3% (731/971). Comparison of those contacted who agreed versus declined to participate revealed a greater proportion of males who declined participation ( P = 0.001). Conclusions Early results of the SJLIFE study support its feasibility to recruit aging childhood cancer survivors to research investigations evaluating late health outcomes by medical assessments. Pediatr Blood Cancer 2011;56:825–836. © 2010 Wiley‐Liss, Inc.